Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.
At Fred Hutch, we believe that the innovation, collaboration, and rigor that result from diversity and inclusion are critical to our mission of eliminating cancer and related diseases. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an antiracist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, antiracism, and inclusion.
Global Oncology, a cross-divisional program within the Director’s Office of Fred Hutchinson Cancer Research Center, has a mission to generate cancer research that has global impact, and support the development research capacity and clinical care to reduce the cancer burden in low- and middle-income countries. A cornerstone of the program is a decade-long alliance with the Uganda Cancer Institute (UCI) that advances research, capacity building, and cancer care. Fred Hutch operates in Uganda as the Hutchinson Centre Research Institute of Uganda, or HCRI-Ug.
The Medical Officer will perform assigned duties for adult participants enrolled in the phase I study of rituximab hyaluronidase in adults and children (U028) at the UCI-Fred Hutch Cancer Centre in Kampala. Led by the Fred Hutch Principal Investigator (PI) and the Uganda Cancer Institute Adult and Pediatric Oncology PIs, this trial aims to optimize a treatment regimen for patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma or Castleman’s disease, while strengthening diagnosis and supportive care. This position will report to the Study Coordinator, and will have dotted line reporting to the study local study PI.
In addition to the minimum qualifications, the ideal candidate will have the following characteristics: